Cargando…
Therapeutic enzyme engineering using a generative neural network
Enhancing the potency of mRNA therapeutics is an important objective for treating rare diseases, since it may enable lower and less-frequent dosing. Enzyme engineering can increase potency of mRNA therapeutics by improving the expression, half-life, and catalytic efficiency of the mRNA-encoded enzym...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795449/ https://www.ncbi.nlm.nih.gov/pubmed/35087131 http://dx.doi.org/10.1038/s41598-022-05195-x |
_version_ | 1784641074046697472 |
---|---|
author | Giessel, Andrew Dousis, Athanasios Ravichandran, Kanchana Smith, Kevin Sur, Sreyoshi McFadyen, Iain Zheng, Wei Licht, Stuart |
author_facet | Giessel, Andrew Dousis, Athanasios Ravichandran, Kanchana Smith, Kevin Sur, Sreyoshi McFadyen, Iain Zheng, Wei Licht, Stuart |
author_sort | Giessel, Andrew |
collection | PubMed |
description | Enhancing the potency of mRNA therapeutics is an important objective for treating rare diseases, since it may enable lower and less-frequent dosing. Enzyme engineering can increase potency of mRNA therapeutics by improving the expression, half-life, and catalytic efficiency of the mRNA-encoded enzymes. However, sequence space is incomprehensibly vast, and methods to map sequence to function (computationally or experimentally) are inaccurate or time-/labor-intensive. Here, we present a novel, broadly applicable engineering method that combines deep latent variable modelling of sequence co-evolution with automated protein library design and construction to rapidly identify metabolic enzyme variants that are both more thermally stable and more catalytically active. We apply this approach to improve the potency of ornithine transcarbamylase (OTC), a urea cycle enzyme for which loss of catalytic activity causes a rare but serious metabolic disease. |
format | Online Article Text |
id | pubmed-8795449 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-87954492022-01-28 Therapeutic enzyme engineering using a generative neural network Giessel, Andrew Dousis, Athanasios Ravichandran, Kanchana Smith, Kevin Sur, Sreyoshi McFadyen, Iain Zheng, Wei Licht, Stuart Sci Rep Article Enhancing the potency of mRNA therapeutics is an important objective for treating rare diseases, since it may enable lower and less-frequent dosing. Enzyme engineering can increase potency of mRNA therapeutics by improving the expression, half-life, and catalytic efficiency of the mRNA-encoded enzymes. However, sequence space is incomprehensibly vast, and methods to map sequence to function (computationally or experimentally) are inaccurate or time-/labor-intensive. Here, we present a novel, broadly applicable engineering method that combines deep latent variable modelling of sequence co-evolution with automated protein library design and construction to rapidly identify metabolic enzyme variants that are both more thermally stable and more catalytically active. We apply this approach to improve the potency of ornithine transcarbamylase (OTC), a urea cycle enzyme for which loss of catalytic activity causes a rare but serious metabolic disease. Nature Publishing Group UK 2022-01-27 /pmc/articles/PMC8795449/ /pubmed/35087131 http://dx.doi.org/10.1038/s41598-022-05195-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Giessel, Andrew Dousis, Athanasios Ravichandran, Kanchana Smith, Kevin Sur, Sreyoshi McFadyen, Iain Zheng, Wei Licht, Stuart Therapeutic enzyme engineering using a generative neural network |
title | Therapeutic enzyme engineering using a generative neural network |
title_full | Therapeutic enzyme engineering using a generative neural network |
title_fullStr | Therapeutic enzyme engineering using a generative neural network |
title_full_unstemmed | Therapeutic enzyme engineering using a generative neural network |
title_short | Therapeutic enzyme engineering using a generative neural network |
title_sort | therapeutic enzyme engineering using a generative neural network |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795449/ https://www.ncbi.nlm.nih.gov/pubmed/35087131 http://dx.doi.org/10.1038/s41598-022-05195-x |
work_keys_str_mv | AT giesselandrew therapeuticenzymeengineeringusingagenerativeneuralnetwork AT dousisathanasios therapeuticenzymeengineeringusingagenerativeneuralnetwork AT ravichandrankanchana therapeuticenzymeengineeringusingagenerativeneuralnetwork AT smithkevin therapeuticenzymeengineeringusingagenerativeneuralnetwork AT sursreyoshi therapeuticenzymeengineeringusingagenerativeneuralnetwork AT mcfadyeniain therapeuticenzymeengineeringusingagenerativeneuralnetwork AT zhengwei therapeuticenzymeengineeringusingagenerativeneuralnetwork AT lichtstuart therapeuticenzymeengineeringusingagenerativeneuralnetwork |